In the United States, Niranjan et al. developed a model in which patients with PSA >3 ng/mL would undergo TRUSBx as part of the standard of care for diagnosing PCa or they would have performed one of three tests (PHI, 4Kscore, SelectMDx). This evidence concerns the gene KLK3 and posterior cortical atrophy.